Health & Environmental Research Online (HERO)


Print Feedback Export to File
6322439 
Journal Article 
Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting 
Diamond, JR, JR; Potter, D; Salkeni, M; Silverman, P; Haddad, T; Forget, F; Awada, A; Canon, JL; Luhn, P; O'Hear, C; Ton, TG; Sanglier, T; Hsieh, R; Oliveri, E; Chuo, J; Xiao, Y; Emens, L 
2019 
Yes 
Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445 
79 
4 
WOS:000478677001420